Detsky AS, Haglie IGA clinician's guide to cost-effectiveness analysisAnn Intern Med1990,113:147.
2.
Durand-Zaleski I., Bastuji-Garin S., Zaleski S., Weil B., Rostoker G.A cost analysis of the prevention of end-stage renal disease. immunoglobulin therapy for IgA nephropathy. Med Decis Making.1996,16:326-34.
3.
Peh CA, Clarkson ARTreatment of IgA nephropathy. Nephrol Dial Transplant.1995,10:1119-21.
Rostoker G., Desvaux-Belghiti D., Pilatte Y., et al. High-dose immunoglobulin therapy for severe IgA nephropathy and Henoch-Schonlein purpura. Ann Intern Med.1994;120: 476-84.
6.
Cucharal GJ, Levery AS, Pauker SGKidney failure or cancer: should immunosupression be continued in a transplant patient with malignant melanoma? Med Decis Making.1984;4: 83.
7.
Consensus Development Conference Panel.Morbidity and mortality of renal dialysis an NIH Consensus Conference statement . Ann Intern Med.1994,121:62-70.
8.
Eisenberg JMClinical economics: a guide to the economic analysis of clinical practicesJAMA.1989;262:2879-86.
9.
Doubilet P., Weinstein MC, McNeil BJUse and misuse of the term "cost-effective" in medicine. N Engl J Med.1986;296: 253-6.
10.
Rettig RAThe social contract and the treatment of permanent kidney failure . JAMA.1996,275:1123-6.
11.
Weinstein MC , Stason WBFoundations of cost-effectiveness analysis for health and medical practices. N Engl J Med.1977;296:716.
